Incyte (INCY) Cash from Investing Activities (2010 - 2026)
Incyte (INCY) reported Cash from Investing Activities of -$88.2 million for Q1 2026, down 8140.38% on a YoY basis from $1.1 million in Q1 2025, and down 135.72% quarter-over-quarter from -$37.4 million in Q4 2025.
Incyte (INCY) Cash from Investing Activities (2010 - 2026) Analysis & Trends
Incyte has reported Cash from Investing Activities for 17 years, with the latest figure at -$88.2 million in Q1 2026.
- For the quarter ending Q1 2026, Cash from Investing Activities fell 8140.38% year-over-year to -$88.2 million; the trailing twelve-month figure through Mar 2026 stood at -$191.9 million (down 182.82% YoY), and the FY2025 full-year result was -$102.6 million, down 165.14% from the prior year.
- Cash from Investing Activities for Q1 2026 stood at -$88.2 million, down from -$37.4 million in the prior quarter.
- The five-year high for Cash from Investing Activities was $213.8 million in Q2 2024, with the low at -$154.5 million in Q4 2023.
- Historically, Cash from Investing Activities has averaged -$18.8 million across 5 years, with a median of -$20.9 million in 2022.
- Annual changes were most pronounced in 2024 — Cash from Investing Activities surged 2978.18% — and 2026, when it tumbled 8140.38%.
- Incyte's Cash from Investing Activities stood at -$20.9 million in 2022, then tumbled by 638.81% to -$154.5 million in 2023, then surged by 86.11% to -$21.5 million in 2024, then tumbled by 74.33% to -$37.4 million in 2025, then sank by 135.72% to -$88.2 million in 2026.
- The last three Cash from Investing Activities figures came in at -$88.2 million (Q1 2026), -$37.4 million (Q4 2025), and -$47.4 million (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Investing Activities (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | -2.89 Mn |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | 638.50 Mn |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | - |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | - |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | - |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | -431.90 Mn |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | 579,519.10 |
| 10 | Incyte | 19.62 Bn | 15.60 Bn | 1.17 Bn | -88.20 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -88.20 Mn |
| Mar 31, 2026 | -88.20 Mn |
| Dec 31, 2025 | -37.42 Mn |
| Dec 31, 2025 | -37.42 Mn |
| Sep 30, 2025 | -47.42 Mn |
| Sep 30, 2025 | -47.42 Mn |
| Jun 30, 2025 | -18.87 Mn |
| Jun 30, 2025 | -18.87 Mn |
| Mar 31, 2025 | 1.10 Mn |
| Mar 31, 2025 | 1.10 Mn |
| Dec 31, 2024 | -21.47 Mn |
| Dec 31, 2024 | -21.47 Mn |
| Sep 30, 2024 | 38.27 Mn |
| Sep 30, 2024 | 38.27 Mn |
| Jun 30, 2024 | 213.82 Mn |
| Jun 30, 2024 | 213.82 Mn |
| Mar 31, 2024 | -73.11 Mn |
| Mar 31, 2024 | -73.11 Mn |
| Dec 31, 2023 | -154.50 Mn |
| Dec 31, 2023 | -154.50 Mn |